KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Non-Current Assets for 13 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 85.05% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, down 85.05% year-over-year, with the annual reading at $2.6 million for FY2025, 85.05% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.6 million at Halozyme Therapeutics, down from $55.7 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $80.2 million in Q3 2024, with the low at $500000.0 in Q3 2021.
  • Average Other Non-Current Assets over 5 years is $19.9 million, with a median of $13.5 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets soared 2996.2% in 2021, then plummeted 96.43% in 2022.
  • Over 5 years, Other Non-Current Assets stood at $2.1 million in 2021, then tumbled by 76.15% to $500000.0 in 2022, then skyrocketed by 3581.8% to $18.4 million in 2023, then decreased by 5.48% to $17.4 million in 2024, then crashed by 85.05% to $2.6 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2.6 million, $55.7 million, and $56.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.